Insta
Serum Institute’s Covishield Vaccine Produces Antibodies Against B.1.617.1 Variant Of Coronavirus: ICMR Study
Swarajya Staff
May 15, 2021, 11:12 AM | Updated 11:12 AM IST
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
The Covishield Covid-19 vaccine, which is being manufactured in India by Serum Institute of India, is effective against the B.1.617.1 strain of the Coronavirus, a study has found.
The B.1.617.1 variant of the Covid-19 virus is considered to be responsible for surge of the cases in India.
A study by the Indian Council of Medical Research (ICMR) has concluded that "Covishield vaccine-induced antibodies are likely to be protective to limit the severity and mortality of the disease in vaccinated individuals”.
"The results demonstrated that sera of COVID-19 recovered subjects (n=18) who received two doses of Covishield have higher NAb response compared to the COVID-19 naive with a significant difference (p<0.0001) in NAb titer against B.1 and B.1.617.1," said the study published in pre-print server bioRxiv.
Till date, over 170 million doses of vaccine have been administered to Indian citizens with two approved vaccines- Covishield (Astrazeneca-Oxford) and Bharat Biotech's Covaxin.
Earlier, the ICMR in a study has said that the indigenous Covid-19 vaccine was effective against the various strains of the Covid-19 virus including B.1.617.1, B.1.1.7, B.1.1.28.2 and variants.
Save & read from anywhere!
Bookmark stories for easy access on any device or the Swarajya app.
Introducing ElectionsHQ + 50 Ground Reports Project
The 2024 elections might seem easy to guess, but there are some important questions that shouldn't be missed.
Do freebies still sway voters? Do people prioritise infrastructure when voting? How will Punjab vote?
The answers to these questions provide great insights into where we, as a country, are headed in the years to come.
Swarajya is starting a project with an aim to do 50 solid ground stories and a smart commentary service on WhatsApp, a one-of-a-kind. We'd love your support during this election season.
Click below to contribute.